Skip to main content
Tessa NewsLink
Paste a health news link, or browse

Source study found

Story checked

US Doctors Just Changed Their Guidelines For Migraine Prevention : ScienceAlert (opens in a new tab)

sciencealert.com · 2026-09-09

Short answerEvidenceSource

Short answer

Not supported

Not supported.

The study does not answer the story's main claims.

  • 6 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Not supported

The study doesn't address any of the story's claims. We found the paper, but it doesn't report the details the story leads with.

  • 6 not covered
Open claim evidence
3
Source paper

Source layer

The 2 papers the story cites

Source study separated from background citations.

The research anchor for the report.

Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

6 claims in this story

Showing all 6 claimsChoose a verdict to focus the list.

Claim 1 of 6Not coveredMedical experts in the US have expanded their recommendations for who should receive migraine treatment and what preventative drugs they should be prescribed.View evidenceHide evidence

Why this verdict

The abstract supports that this is an updated evidence-based practice guideline on when to start migraine preventive pharmacologic therapy and what medication to start. However, the story’s headline framing that recommendations were specifically 'expanded' for eligibility and drug prescribing is a comparison with prior guidance that is not documented in the abstract-level profile. The headline therefore goes beyond what can be verified at this depth.

1

Study evidence

Guidance on when to start pharmacologic migraine preventive medication (criteria for initiating preventive therapy).

“This practice guideline provides updated evidence‐based recommendations regarding the use of pharmacologic migraine prevention in adults.”
Claim 2 of 6Not coveredA panel of experts systematically analyzed the available evidence and updated a 2012 joint guideline from the American Academy of Neurology and the American Headache Society.View evidenceHide evidence

Why this verdict

The abstract supports that a multidisciplinary panel conducted a systematic review and developed recommendations using the AAN guideline process. But the specific claim that this updated a 2012 joint AAN/AHS guideline is not available in the abstract-level profile, so the full claim cannot be verified at this depth.

1

Study evidence

Guidance on when to start pharmacologic migraine preventive medication (criteria for initiating preventive therapy).

“This practice guideline provides updated evidence‐based recommendations regarding the use of pharmacologic migraine prevention in adults.”
Claim 3 of 6Not coveredThe new recommendations, published in Headache and endorsed by the American Academy of Family Physicians, say clinicians should offer preventive treatments to patients with migraine who have four or more moderate-to-severe headaches or migraine attacks a month, or who have substantial migraine-related disability.View evidenceHide evidence

As statedfour or more moderate-to-severe headaches or migraine attacks a month

Why this verdict

The abstract supports that the guideline gives recommendations on when to start pharmacologic migraine prevention, but it does not provide the specific initiation threshold of four or more moderate-to-severe headache or migraine days per month, the substantial-disability criterion, publication venue details, or AAFP endorsement. These specifics require full-text or other profile evidence beyond the abstract.

1

Study evidence

Guidance on when to start pharmacologic migraine preventive medication (criteria for initiating preventive therapy).

“This practice guideline provides updated evidence‐based recommendations regarding the use of pharmacologic migraine prevention in adults.”
Claim 4 of 6Not coveredThe rationale for the change is that many migraine-prevention trials enroll people with four or more migraines a month and that headache frequency predicts progression from episodic to chronic migraine.View evidenceHide evidence

As statedfour or more migraines a month

Why this verdict

The abstract says recommendations are supported by structured rationales integrating systematic-review evidence, related evidence, principles of care, and inferences. It does not provide the specific rationale that trials enroll people with at least four migraines per month or that headache frequency predicts progression to chronic migraine. This rationale is therefore not verifiable at abstract depth.

1

Study evidence

Guidance on when to start pharmacologic migraine preventive medication (criteria for initiating preventive therapy).

“This practice guideline provides updated evidence‐based recommendations regarding the use of pharmacologic migraine prevention in adults.”
Claim 5 of 6Not coveredAtogepant, erenumab, fremanezumab, galcanezumab, and eptinezumab are now recommended as first-line pharmaceutical options for people experiencing migraine, and botox is also recommended for chronic migraine.View evidenceHide evidence

Why this verdict

The abstract supports that the guideline includes recommendations on medication selection, but it does not name atogepant, erenumab, fremanezumab, galcanezumab, eptinezumab, or botox/onabotulinumtoxinA, nor does it state first-line status or chronic-migraine-specific recommendations. These drug-specific claims are not verifiable from the abstract-level profile.

1

Study evidence

Guidance on when to start pharmacologic migraine preventive medication (criteria for initiating preventive therapy).

“This practice guideline provides updated evidence‐based recommendations regarding the use of pharmacologic migraine prevention in adults.”
Claim 6 of 6Not coveredThe guidelines say some preventive drugs have more side effects or unknown long-term harms, and after six months of preventive treatment clinicians should discuss tapering while noting migraine attacks may become more frequent after stopping medication.View evidenceHide evidence

As statedafter six months of preventive treatment

Why this verdict

The abstract supports that the guideline addresses adverse-effect monitoring and discontinuation of preventive medications. It does not provide the specific six-month tapering discussion, claims about unknown long-term harms, or evidence about attack frequency after stopping medication. The story’s detailed discontinuation and harm statements are not verifiable at this depth.

1

Study evidence

Guidance on when to start pharmacologic migraine preventive medication (criteria for initiating preventive therapy).

“This practice guideline provides updated evidence‐based recommendations regarding the use of pharmacologic migraine prevention in adults.”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • The guideline addresses special populations and comorbidities, including fibromyalgia, obesity, hypertension, older adults, pregnancy/lactation, sex-related factors, and medication overuse.

    These population- and comorbidity-specific recommendation areas are material in the abstract profile but are not reflected in the presented story claims or caveats.

    From Guideline development using AAN Clinical Practice Guideline Process Manual (2017)

  • Some recommendations integrate related evidence and inferences in addition to direct systematic-review evidence.

    This is an interpretation-relevant limitation in the profile. The story mentions limited evidence about stopping medication but does not convey the broader caveat that some recommendations may rely on indirect evidence or inference rather than direct trial evidence.

    From Guideline development using AAN Clinical Practice Guideline Process Manual (2017)

  • The evidence base covered studies available through June 6, 2024.

    The profile states the evidence coverage date, but the story presentation does not mention this evidence cutoff.

    From Guideline development using AAN Clinical Practice Guideline Process Manual (2017)

5 things the story did carry across
  • The paper is an updated evidence-based practice guideline for pharmacologic prevention of migraine in adults, addressing when to start preventive medication and what to start.
  • Recommendations were developed by a multidisciplinary panel using the AAN Clinical Practice Guideline Process Manual and were supported by a systematic review reported in a companion publication.
  • The guideline includes criteria for initiating pharmacologic migraine preventive therapy, but the abstract does not give the specific criteria or recommendation strengths.
  • The guideline includes recommendations on choosing preventive medications, including considerations across agents and patient factors.
  • The guideline addresses assessing treatment efficacy, monitoring adverse effects, and discontinuing preventive medications.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

1

Evidence read

study summary

Lead result

other

1Lead resultotherProvide updated evidence-based practice guideline recommendations for pharmacologic prevention of migraine in adults (including when to start, what to start, and how to monitor/stop), based on a systematic review and AAN guideline-development processes.Guideline development using AAN Clinical Practice Guideline Process Manual (2017)Expand

In plain English

Practice guideline providing updated evidence-based recommendations for pharmacologic prevention of migraine in adults. A multidisciplinary panel used the American Academy of Neurology (AAN) Clinical Practice Guideline Process Manual (2017) to develop recommendations supported by a systematic review (search through June 6, 2024; systematic review reported in a companion publication). The document gives guidance on when to start preventive medication, how to choose agents across general and specific patient situations (including fibromyalgia, obesity, hypertension, older adults, pregnancy/lactation, sex-related factors, and medication overuse), and on assessing efficacy, adverse effects, and discontinuation. Recommendations are accompanied by structured rationales that integrate evidence from the systematic review, related evidence, principles of care, and inference from evidence.

Key findings

  • Guidance on when to start pharmacologic migraine preventive medication (criteria for initiating preventive therapy).
  • Recommendations on how to decide which migraine preventive medication to start, including considerations across different agents and patient factors.
“This practice guideline provides updated evidence‐based recommendations regarding the use of pharmacologic migraine prevention in adults.”
What this piece can’t prove
  • This record is a practice guideline summary (abstract); the systematic-review methods and detailed evidence syntheses are reported in a companion publication and are not included here.
  • The abstract does not provide specific recommendation statements, grades/strengths, or supporting data; interpretation of the guideline content requires consulting the full guideline document.
  • The guideline integrates related evidence and inferences in addition to systematic-review findings, so some recommendations may rely on indirect evidence as indicated by the authors.
  • Evidence coverage limited to studies available through June 6, 2024.
Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

Crossref, PubMed, Europe PMC · 17 candidate papers

And 11 more candidates considered.